Navidea Biopharmaceuticals Inc.
NAVB
NAVB was delisted on the 5th of October, 2023.
29 hedge funds and large institutions have $379K invested in Navidea Biopharmaceuticals Inc. in 2019 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 7 increasing their positions, 4 reducing their positions, and 4 closing their positions.
75% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 4
50% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 4
7% more funds holding
Funds holding: 27 → 29 (+2)
3% less capital invested
Capital invested by funds: $392K → $379K (-$13K)
70% less call options, than puts
Call options by funds: $14K | Put options by funds: $47K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$16.3K |
| 2 |
Group One Trading
Chicago,
Illinois
|
+$11.9K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$7.47K |
| 4 |
ARTA
A.R.T. Advisors
New York
|
+$6.32K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$2.81K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WS
Wedbush Securities
Los Angeles,
California
|
-$56K |
| 2 |
VF
Virtu Financial
New York
|
-$28.1K |
| 3 |
Jane Street
New York
|
-$12K |
| 4 |
ACM
Allred Capital Management
Dallas,
Texas
|
-$4.98K |
| 5 |
Citigroup
New York
|
-$78 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
26
Jane Street
New York
| – | -$12K | -19,474 | Closed |
|
27
CAPTRUST Financial Advisors
Raleigh,
North Carolina
| – | +$2 | +4 | New |
|
|
IA
28
IFP Advisors
Tampa,
Florida
| – | +$31 | +50 | New |
|
NAVB Hedge Fund Activity: Q3 2019 in Review
29 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Navidea Biopharmaceuticals Inc. (NAVB) for Q3 2019, worth a combined $379K — down 3.3% from $392K a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new NAVB positions and 4 closed out — a net gain of 2 holders — while 7 added to existing stakes and 4 trimmed.
The largest buyer was Vanguard Group, adding an estimated $16.3K. The largest seller was Wedbush Securities, exiting entirely with an estimated $56K sold.
- 29 institutional investors held Navidea Biopharmaceuticals Inc. (NAVB) as of Q3 2019, up from 27 in Q2 2019.
- Funds reported $379K of Navidea Biopharmaceuticals Inc. stock for Q3 2019, down 3.3% quarter-over-quarter.
- 6 funds opened new Navidea Biopharmaceuticals Inc. positions in Q3 2019 and 4 closed out, a net change of +2 holders.
- The largest Navidea Biopharmaceuticals Inc. buyer in Q3 2019 was Vanguard Group, an estimated $16.3K added.
- The largest Navidea Biopharmaceuticals Inc. seller in Q3 2019 was Wedbush Securities, an estimated $56K sold.
Based on aggregated 13F filings for Q3 2019.